Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY

https://doi.org/10.17749/2070-4909.2016.9.3.038-047

Full Text:

Abstract

Aims of study: 1) development of a model for forecasting of impact of Lacosamide administration for antiseizure therapy of local convulsions in patients, who are resistant to previous antiseizure therapy, for the account of healthcare and social security budget of the constituent members of the Russian Federation; 2) assessment of clinical and economical feasibility of Lacosamide administration from the point of view of healthcare and social security budget of the constituent members of the Russian Federation, by example of Kaliningrad region.

Materials and methods. General model of Microsoft Excel was developed for analysis of impact of Lacosamide administration to healthcare and social security budget of the constituent members of the Russian Federation in three scenarios: Lacosamide as concomitant drug to standard therapy in comparison with standard therapy without Lacosamide (scenario 1), Lacosamide in comparison with Perampanel, both as concomitant drug to standard therapy (scenario 2) and early administration of Lacosamide as the first concomitant drug to standard monotherapy in comparison with its late administration (scenario 3). The Model allows calculation of the direct medical costs (for the drugs and medical services) and direct non-medical costs (payment of temporary and permanent disability allowances) from the point of view of healthcare and social security system of a constituent member of the Russian Federation. The simulation uses the results of clinical studies and meta-analyses of the antiseizure drugs under consideration, data of state statistical monitoring, and results of previous epilepsy burden analysis conducted in the Russian Federation. The costs in model are calculated on the basis of registered prices on drugs from the List of vital and essential medicines (VEM), price of public purchases of drugs and regulations of financial costs per unit of medical aid in Russia in 2015. We conducted the analysis of impact of Lacosamide administration to the budget of the constituent member of the Russian Federation by example of Kaliningrad region.

Results. Scenario 1: in case of increase of total costs by 6.75%; 10.42% and 17.38% in the first, second and third year respectively, administration of Lacosamide as concomitant drug, in comparison with standard therapy without Lacosamide, allows to obtain additional therapy response in 4, 6, 11 patients and remission in 1, 1 and 2 patients, who are resistant to the previous antiseizure therapy. Scenario 2: Taking into consideration the commeasurable efficacy and safety, the economic advantages of Lacosamide over Perampanel are 1.64, 2.65, 4.74 million rubles in the first, second and third year respectively. Scenario 3: administration of Lacosamide as the first concomitant drug after the failed monotherapy allows reaching of the increased therapy response rate and remissions number in comparison with Lacosamide administration as the second concomitant drug and reduce the budget expenses for antiseizure therapy by 11.45 and 1.85 million rubles in the first and the second year respectively.

About the Authors

E. A. Pyadushkina
Russian Presidential Academy of National Economy and Public Administration, Moscow
Russian Federation

research fellow of Laboratory for health technology assessment of Applied economic research Institute of Russian academy of national economy and public administration. Address: Vernadskogo prospect, 82-1, Moscow, Russia, 119571, RANEPA IPEI, Laboratory for health technology assessment. Tel.: +7(499)9569528, +7(499)9569529



M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health Russian Federation
Russian Federation

PhD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department of Volgograd state medical university. Address: Pavshih borzov pl., 1, Volgograd, Russia, 400131



References

1. Avakyan G. N. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 4: 46-49.

2. Aivazyan S. O., Luk’yanova E.G., Shiryaev Yu.S. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 1: 34-43.

3. Vlasov P. N. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2015; 4: 40-49.

4. Blinov D. V. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2011; 2: 28-33.

5. Bochanova E. N., Zhuravlev D. A., Nozdrachev K. G ., Bogdanov V. V., Shnaider N. A., Dmitrenko D. V., Kozhukhova E. I., Bikulova T. V. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2015; 3: 32-39.

6. G romov S. A., Yakunina O. N. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2015; 2: 18-24.

7. Belousov D. Yu., Afanas’eva E.V., Efremova E. A. Kachestvennaya klinicheskaya praktika. 2014; 1: 24-39.

8. Belousov D. Y u., Beketov A. S., Mednikov O. I. Farmateka. 2005; 6: 116-129.

9. Brodi M. Mezhdunarodnyi nevrologicheskii zhurnal. 2005; 4: 72-83.

10. G ekht A. B., Avakyan G. N., Gusev E. I. Zhurn nevrol i psikhiat. 1999; 99 (7): 4-7.

11. Standard: Health Technology Assessment. General provisions. GOST R 56044-2014 [GOST: Otsenka meditsinskikh tekhnologii. Obshchie polozheniya. GOST R 56044-2014 (in Russian)].

12. Instructions for use of the drug for medical use Vimpat. Reg. number: RL- 009187/09 [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Vimpat. Reg. nomer: LRS-009187/09 (in Russian)]. URL: http://grls.rosminzdrav.ru/Grls_View.aspx?idReg=11725&isOld=1&t=. Accessed: 26.10.2014.

13. Omel’yanovskii V. V., Avksent’eva M. V., Derkach E. V, Margieva A. V. The report on research work «Assessment of the socio-economic burden of epilepsy in the Russian Federation» in 2012 (accepted for publication) [Otchet o nauchno-issledovatel’skoi rabote «Otsenka sotsial’noekonomicheskogo bremeni epilepsii v Rossiiskoi Federatsii» 2012 god (Article on materials accepted for publication) (in Russian)].

14. Order of the Russian Ministry of Health from 24.12.2012 N 1404n «On approval of the standard of primary health care with partial epilepsy (Phase diagnosis and selection of therapy) [«Prikaz Minzdrava Rossii ot 24.12.2012 N 1404n «Ob utverzhdenii standarta pervichnoi mediko-sanitarnoi pomoshchi pri partsial’noi epilepsii (faza diagnostiki i podbora terapii)» (in Russian)].

15. Statistical Yearbook FGBI «FPHI» Russian Ministry of Health, «The incidence of the entire population of the Russian Federation in 2013» [Statisticheskii sbornik FGBU «TsNIIOIZ» Minzdrava Rossii «Zabolevaemost’ vsego naseleniya Rossiiskoi Federatsii v 2013 godu» (in Russian)]. URL: http://www.mednet.ru/ru/statistika/zabolevaemostnaseleniya/zabolevaemost-vsego- naseleniya.html. Accessed: 18.07.2015.

16. Statistical Yearbook FGBI «FPHI» Russian Ministry of Health, «The incidence of the adult population of the Russian Federation in 2011» [Statisticheskii sbornik FGBU «TsNIIOIZ» Minzdrava Rossii «Zabolevaemost’ vzroslogo naseleniya Rossiiskoi Federatsii v 2011 godu» (in Russian)]. URL: http://www.mednet.ru/ru/statistika/zabolevaemost-naseleniya.html. Accessed: 01.07.2014.

17. Statistical Yearbook FGBI «FPHI» Russian Ministry of Health, «The incidence of the adult population of the Russian Federation in 2012» [Statisticheskii sbornik FGBU «TsNIIOIZ» Minzdrava Rossii «Zabolevaemost’ vzroslogo naseleniya Rossiiskoi Federatsii v 2012 godu» (in Russian)]. URL: http://www.mednet.ru/ru/statistika/zabolevaemost-naseleniya.html. Accessed: 01.07.2014.

18. Statistical Yearbook FGBI «FPHI» Russian Ministry of Health, «The incidence of the adult population of the Russian Federation in 2013» [Statisticheskii sbornik FGBU «TsNIIOIZ» Minzdrava Rossii «Zabolevaemost’ vzroslogo naseleniya Rossiiskoi Federatsii v 2013 godu» (in Russian)]. URL: http://www.mednet.ru/ru/statistika/zabolevaemost-naseleniya.html. Accessed: 01.07.2014.

19. The tariff agreement for medical care payment system of compulsory medical insurance of the Kaliningrad region for 2015 [Tarifnoe soglashenie na oplatu meditsinskoi pomoshchi v sisteme obyazatel’nogo meditsinskogo strakhovaniya Kaliningradskoi oblasti na 2015 god (in Russian)].

20. Territorial program of state guarantees of free medical care for 2015 and the planning period of 2016 and 2017 in the Kaliningrad region [Territorial’naya programma gosudarstvennykh garantii besplatnogo okazaniya meditsinskoi pomoshchi na 2015 god i na planovyi period 2016 i 2017 godov v Kaliningradskoi oblasti (in Russian)].

21. The Federal State Statistics Service. Expedite information on topical issues: On the cash income ratio of population to subsistence level and the number of poor in the whole of the Russian Federation [Federal’naya sluzhba gosudarstvennoi statistiki. Crochnaya informatsiya po aktual’nym voprosam: O sootnoshenii denezhnykh dokhodov naseleniya s velichinoi prozhitochnogo minimuma i chislennosti maloimushchego naseleniya v tselom po Rossiiskoi Federatsii (in Russian)]. URL: http://www.gks.ru/bgd/free/B09_03/IssWWW.exe/Stg/d04/260.htm. Accessed: 01.07.2014.

22. E pilepsy. Newsletter №999 from October 2012, the World Health Organization [Epilepsiya. Informatsionnyi byulleten’ №999 ot oktyabrya 2012 g. Vsemirnaya organizatsiya zdravookhraneniya (in Russian)]. URL: http://www.who.int/mediacentre/factsheets/fs999/ru/. Accessed: 11.05.2015.

23. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48 (7): 1308-1317.

24. Chung S., Sperling M. R., Biton V., Krauss G., Hebert D., Rudd G. D., Doty P. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010b; 51 (6): 958-967.

25. Kwan P., Arzimanoglou A., Berg A. T., Brodie M. J., Allen Hauser W., Mathern G., Moshé S. L ., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51 (6): 1069-1077.

26. Costa J., Fareleira F., Ascencao R., Borges M., Sampaio C., Vaz- Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011; 52 (7): 1280-1291.

27. H al´asz P., Kalviainen R., Mazurkiewicz-Beldzinska M., Rosenow F., Doty P., Hebert D., Sullivan T. On behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009; 50 (3): 443-453.

28. Khan, Nasreen et al. The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis. Current Medical Research & Opinion. 2013; 29 (8): 1001-1013.

29. Mauskopf J. A., Sullivan S. D., Annemans L. et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value in health. 2007; 10 (5): 336-347.

30. National Institute for Clinical Excellence. «The Epilepsies. The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care». NICE guidelines [CG137] 2012. URL: http://www.nice.org.uk/guidance/cg137/chapter/appendix-epharmacological-treatment. Accessed: 07.08.2015.

31. Sawh S. C., Newman J. J., Deshpande S., Jones P. M. Lacosamide adjunctive therapy for partial-onset seizures: a metaanalysis. PeerJ. 2013; 1: e114.

32. Villanueva V., Garcés M., López-Gomáriz E V., López-Gomáriz E. et al. Early Add- on Lacosamide in a Real-Life Setting: Results of the REALLY Study. Clinical drug investigation. 2015; 35 (2): 121-131.


For citation:


Pyadushkina E.A., Frolov M.Y. CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2016;9(3):38-47. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.3.038-047

Views: 343


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)